Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.
Hum Pathol. 2010 Jun;41(6):824-31. doi: 10.1016/j.humpath.2009.11.007. Epub 2010 Feb 12.
Intraductal papillary mucinous neoplasms of the pancreas are subclassified based on morphological features, and different immunohistochemical profiles have been identified in association with the subtypes. We previously reported that S100P was an early developmental marker of pancreatic carcinogenesis and that there was higher S100P expression in intraductal papillary mucinous neoplasms than in normal pancreatic ductal epithelium. However, there have been no reports on novel diagnostic markers to distinguish intraductal papillary mucinous neoplasm from nonneoplastic lesions. Surgical specimens of intraductal papillary mucinous neoplasm obtained from 105 patients were investigated using immunohistochemistry. S100P expression was not detected in normal pancreatic ductal epithelium but was detected in all intraductal papillary mucinous neoplasm cells (100%) with diffuse nuclear or nuclear/cytoplasmic staining. MUC5AC was also expressed in most of the intraductal papillary mucinous neoplasms (102/105; 97%). Furthermore, S100P was clearly expressed in the invasive component of intraductal papillary mucinous neoplasms (32/32; 100%), including perineural and lymphatic and minimal invasion. On the other hand, MUC5AC was expressed in only 23 cases of 32 invasive components (P < .01). These data suggest that the S100P antibody may be a useful marker for detecting all types of intraductal papillary mucinous neoplasms.
胰腺导管内乳头状黏液性肿瘤（Intraductal papillary mucinous neoplasms of the pancreas）根据形态学特征进行分类，并且已经确定与亚型相关的不同免疫组织化学特征。我们之前报道过 S100P 是胰腺癌变的早期发育标志物，并且在导管内乳头状黏液性肿瘤中的表达高于正常胰腺导管上皮。然而，目前尚无用于区分导管内乳头状黏液性肿瘤与非肿瘤病变的新型诊断标志物的报道。使用免疫组织化学方法对 105 例患者的导管内乳头状黏液性肿瘤手术标本进行了研究。S100P 在正常胰腺导管上皮中未检测到，但在所有导管内乳头状黏液性肿瘤细胞（100%）中均检测到弥漫性核或核/细胞质染色。MUC5AC 也在大多数导管内乳头状黏液性肿瘤（102/105；97%）中表达。此外，S100P 在导管内乳头状黏液性肿瘤的侵袭性成分（32/32；100%）中明显表达，包括神经周围和淋巴以及微小浸润。另一方面，MUC5AC 仅在 32 个侵袭性成分中的 23 个病例中表达（P <.01）。这些数据表明，S100P 抗体可能是检测所有类型导管内乳头状黏液性肿瘤的有用标志物。
